ABSTRACT

Molecular signature of human lung cancer initiating cells

According to the invention there is provided a biomarker, CD166, capable of distinguishing lung cancer stem cells that initiate tumerogenesis. Antagonists to lung cancer cells expressing CD166 able to decrease the tumorigenesis of lung cancer both in vitro and in vivo providing compounds to treat lung cancer. Lung cancer stem cells and cell lines, lung cancer spheres and tissue for screening of antagonists to lung cancer stem cells.

Figure 9B